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Introduction. Neuropsychiatric symptoms in Parkinson’s disease can be assessed by the MDS-UPDRS part IA. The Scale for
Evaluation of Neuropsychiatric Disorders in Parkinson’s disease (SEND-PD) has been recently developed to assess the severity
of some neuropsychiatric symptoms. The objective of this study is to compare the performance of the SEND-PD with the
corresponding items of theMDS-UPDRSpart IA.Methods. Patients with Parkinson’s diseasewere evaluated using theMDS-UPDRS
and the SEND-PD by independent raters. Partial SEND-PD and neuropsychiatric MDS-UPDRS part IA were constructed with
equivalent items for comparison. Results. A total of 260 consecutive patients were included. Overall, 61.2% of the patients did not
report any psychotic symptom and 83.5% did not report any ICD symptom. On the other hand, 78.5% of the patients did report
at least one symptom related to apathy, depression, or anxiety. The partial SEND-PD score was 2.9 ± 3.1 (range from 0 to 16). The
neuropsychiatric MDS-UPDRS part IA score was 2.9 ± 3 (range from 0 to 14). The correlation coefficient between corresponding
items ranged from 0.67 to 0.98 and between both summary indexes was 𝑟
𝑠
= 0.93 (all, 𝑃 < 0.001). Conclusion. A high association
between equivalent items of the SEND-PD and the MDS-UPDRS was found.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease
characterized by both motor and nonmotor symptoms.
Neuropsychiatric symptoms are amongst the most common
nonmotor features of PD [1].
The International Parkinson and Movement Disorder
Society has issued several recommendations for the use
of clinical scales for the assessment of neuropsychiatric
symptoms [2–5]. Unfortunately most of these instruments
are time consuming, focused on a particular domain, and
nonspecific for PD.Thus, a brief, comprehensive, and specific
clinical instrument for neuropsychiatric symptoms screening
and basic evaluation is of great value for neurologists.
TheMDS-UPDRS part IA (Movement Disorders Society-
Unified Parkinson’s Disease Rating Scale) evaluates non-
motor symptoms in PD subjects and it has been shown
to correlate with several validated scales for the nonmotor
aspects of the disease [6, 7]. Neuropsychiatric and cognitive
symptoms assessed by the MDS-UPDRS part IA include
cognitive decline, hallucinations/psychosis, depressivemood,
anxiety, apathy, and dopaminergic disregulation syndrome.
The Scale for Evaluation of Neuropsychiatric Disorders in
Parkinson’s Disease (SEND-PD) has been recently developed
to assess the severity of some neuropsychiatric symptoms
prominent in this disease [8]. The SEND-PD evaluates the
presence and severity of psychotic symptoms, mood/apathy,
and impulse control disorders (ICD).
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The SEND-PD performance has not been compared with
the MDS-UPDRS part IA. The objective of the present study
is to analyze the convergent validity of the SEND-PDwith the
corresponding components of the MDS-UPDRS part IA.
2. Materials and Methods
We included consecutive PD patients attending the Move-
ment Disorders Clinic at the Neurology and Neurosurgery
National Institute in Mexico City. PD was diagnosed accord-
ing to the Queen Square Brain Bank Criteria [9]. Demo-
graphic data including gender, age, and years of formal
education were collected. Clinical data regarding age at PD
onset, predominant symptoms at PD onset, and current
treatment and dosewere collected. Levodopa equivalent daily
dose (LEDD) was calculated [10]. PD patients were evaluated
by a neurologist with expertise in movement disorders using
the Spanish version of the Movement Disorder Society-
Unified Parkinson Disease Rating Scale (MDS-UPDRS) [11].
Disease severity was determined according to the Hoehn and
Yahr staging [12].
Neuropsychiatric symptoms were assessed using the
Spanish version of the SEND-PD by an independent rater
blinded to the MDS-UPDRS score. The SEND-PD is 12-item
scale designed to measure the presence and severity of neu-
ropsychiatric symptoms. It uses a 5-point Likert scale (scores
0–4 for each question) to rate the severity of symptoms.
Scores for psychotic symptoms range from 0 to 16; scores
for mood/apathy ranges from 0 to 20; and scores for ICDs
range from 0 to 12. In all cases a higher score indicates greater
severity.
When patients showed a significant cognitive decline,
or any other condition preventing them from filling the
questionnaires, the information was obtained from patients
and their caregivers or directly from the caregivers.
The local ethics and research committee approved this
study. All participants provided written informed consent as
determined by the local ethics committee.
2.1. Statistical Analysis. Demographic data were reported in
terms of percentage and mean and standard deviation.
As main data were ordinal or did not fit normal distribu-
tion, nonparametric statistics were used.The floor and ceiling
effect up to 15% [13] and the skewness between −1 and +1
[14] were considered acceptable. Internal consistency of the
SEND-PD subscales was explored by corrected item-domain
correlation andCronbach’s alpha. Values≥0.30 [15] and≥0.70
[16], respectively, were considered appropriate. Correlations
between corresponding items of the SEND-PD and MDS-
UPDRS part IA and between a “partial SEND-PD score”
(items 4, 6, 8, 9, and 12) and the corresponding “partial MDS-
UPDRSpart IANeuropsychiatric score” (items 1.2 to 1.6)were
determined for this study. Spearman’s correlation coefficient
values between 0.30 and 0.70 were considered “moderate”
and those >0.70 were considered “high” [17]. Internal validity
of the SEND-PD was determined by interdomain correla-
tions, with values from 0.30 to 0.70 deemed satisfactory [15].
Table 1: Frequency∗ of neuropsychiatric symptoms assessed by the
MDS-UPDRS part IA and SEND-PD.
MDS-UPDRS IA SEND-PD 𝑃
Hallucinations/psychosis 52 (20%) 49 (18.8%) 0.82
Depression 158 (60.8%) 160 (61.5%) 0.92
Anxiety 114 (43.8%) 116 (44.6%) 0.92
Apathy 95 (36.5%) 86 (33.1%) 0.46
Dopamine dysregulation
syndrome 9 (3.5%) 8 (3.1%) 0.81
∗Frequency of responses >0 for each item.
3. Results
A total of 260 (53.1% male and 46.9% female) consecutive
patients were included. The age of the sample (mean ±
SD) was 62.4 ± 13.1 years and the mean years of schooling
were 8.4 ± 5.2. Mean age of onset of disease was 55 ± 13.8
years (mean disease duration of 7.1 ± 5.4 years). Tremor-
dominant form of Parkinson’s disease was present in 60.8%
of the patients. Regarding the Hoehn and Yahr stage, 69.6%
of the sample had a mild disease (HY 1-2), 18.1% had a
moderate disease (HY 3), and 12.3% had a severe disease.
Regarding the antiparkinsonian treatment, 71.9% were on
levodopa and 56.2% were on a dopamine agonist. Mean
levodopa equivalent daily dosage was 584.2 ± 432.5mg.
Motor fluctuations were present in 13.6%, dyskinesia was
in 24.4%, and freezing was in 25.2%. A total of 32 patients
(12.3%) had dementia by clinical judgment.
Full SEND-PD and MDS-UPDRS were computable for
all patients. The SEND-PD and MDS-UPDRS part I were
responded by patients alone (76.5%), caregiver (1.2%), or by
both patients and caregivers (22.3%).
MDS-UPDRS part I score was 12.1 ± 6.5; MDS-UPDRS
part II score was 14.1 ± 9.8; MDS-UPDRS part III was 34.1 ±
18.8 and part IV was 2 ± 3.8.
The distribution of scores, acceptability, and internal
consistency analyses of each SEND-PD subscale are shown
in the Table 2. Overall, 61.2% of the patients did not report
any psychotic symptom and 83.5% did not report any ICD
symptom. On the other hand, 78.5% of the patients did
report at least one symptom related to apathy, depression,
or anxiety. The frequency of neuropsychiatric symptoms as
reported in both the MDS-UPDRS part IA and SEND-PD
is shown in Table 1. Power calculation for prevalence was
carried out taking into account the lowest prevalence with
any scale (0.031 for dopaminergic dysregulation in the SEND-
PD). Considering a sample of 260 subjects, for a two-sided
test to detect a proportion of 0.031 given a null mean of 0.01
and assuming a 5% significance level, the power is 0.80.There
was no statistically significant difference in SEND-PD scores
between men and women (5.1 ± 6.1 versus 5.4 ± 6, 𝑃 = 0.67).
There was no relevant ceiling effect for the whole SEND-
PDor any of its domains. Floor effect was 17.3% for the SEND-
PD, being higher for the ICDs and psychotic symptoms
subscales (83.5% and 61.2%, resp.). Cronbach’s alpha was
<0.70 only for the ICDs subscale (alpha = 0.53) and only
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Mean ± SD 1.1 ± 2.1 3.8 ± 4 0.4 ± 1.1
Median (IR) 1 5 0
Range 0–14 0–19 0–8
Skewness 3.3 1.4 3.9
Cronbach’s 𝛼 0.73 0.82 0.52
Corrected item-total
correlation 0.40–0.68 0.59–0.64 0.21–0.46
Floor effect (%) 61.2% 21.5% 83.5%
Ceiling effect (%) 0% 0% 0%
SD: standard deviation. IR: interquartile range.
one item (SEND-PD 12, dopaminergic drug abuse/addiction)
showed corrected item-domain correlation <0.30 (𝑟 = 0.21).
Table 3 shows the convergent validity between the SEND-
PD and other related measures of the MDS-UPDRS part
IA. A very high correlation coefficient was found between
hallucinations item 4 of the SEND-PD and the corresponding
item 1.2 of the MDS-UPDRS part IA (𝑟
𝑠
= 0.92), as well as
between depression and anxiety related items (𝑟
𝑠
= 0.96 and
0.98, resp.). Dopaminergic dysregulation syndrome item also
had a high correlation but it should be mentioned that the
frequency of this disorder was very low. Apathy was the item
showing the lower correlation, although it was still moderate.
The partial SEND-PD score was 2.9 ± 3.1 (range from
0 to 16). The neuropsychiatric MDS-UPDRS part IA score
was 2.9 ± 3 (range from 0 to 14). The correlation coefficient
between both resumed indexes was high (𝑟
𝑠
= 0.93,
𝑃 < 0.001). Concerning the internal validity, correlation
coefficient values ranged from0.38 (psychotic symptomswith
mood/apathy) to 0.27 (mood/apathy with ICDs).
4. Discussion
With the growing understanding of neuropsychiatric symp-
toms and other nonmotor manifestations in Parkinson’s
disease (PD), this entity is no longer conceptualized as a pure
motor disorder. Among these symptoms, impulse control
disorders, psychosis, and depression/apathy stand out due
to the important detrimental consequences. Impulse control
disorders are characterized by a failure to resist an impulse
to perform an activity that is harmful to the person or to
others, due to its excessive nature [18]. ICDs may raise severe
social, economic, and legal issues for both patients and their
caregivers. The frequency of ICDs has been reported to be
13.6% [19]. The assessment and diagnosis of an ICD usually
require the use of extended and time-consuming clinical
scales such as the Minnesota Impulsive Disorders Interview.
The Questionnaire for Impulsive-Compulsive Disorders has
been validated for PD as a screening instrument [20] but may
also result in being time consuming when applied along with
other neuropsychiatric scales.TheMDS-UPDRShas only one
item for assessing ICDs, specifically termed as dopaminergic
dysregulation syndrome.
Hallucinations and psychotic symptoms present in 30%–
40%of patients with PD [21, 22]. In regard to psychotic symp-
toms no PD-specific scale has been completely validated.The
presence of hallucinations and other psychotic symptoms is
usually evaluated through the use of instruments designed
for schizophrenic disorders such as the Positive and Negative
Symptom Scale or the Brief Psychiatric Rating Scale [4].
The prevalence of apathy has been reported to be between
17% and 51% [23], while depression is found in around 30
to 40% [24, 25]. Several scales have been recommended for
screening and diagnosis of apathy and depression in patients
with Parkinson’s disease [2, 3]; nevertheless most of them are
not suitable for routinely screening in an outpatient clinic
setting.
The SEND-PD scale was designed to evaluate psychotic
symptoms, mood, apathy, and impulse control disorders in a
simple and relatively fast way [8].
In the present study, data quality was adequate and
skewness values were slightly higher than the accepted upper
limit. This fact is consistent with the floor effect subsequent
to the high proportion of patients who did not experience
the symptoms included in some domains. A high floor
effect was also reported in the first validation study of
the scale [8]. Nevertheless, the floor effect found in our
sample was approximately 10% higher in all the subscales
and probably reflects the lower global disease severity in our
sample. Internal consistency index (Cronbach’s alpha) for
ICDs subscale was below the adequacy criterion. Cronbach’s
alpha is influenced by the distribution of scores in the sample
and the number of items in the scale, two factors that can
explain the relatively low value of this index for the ICD
dimension (three items). In addition to differences in the
assessed constructs, the low prevalence of ICDs also can
explain the loose association of this dimension with the other
domains composing the SEND-PD.
The SEND-PD was originally validated using the Scales
for Outcomes in Parkinson’s Disease-Psychiatric Compli-
cations (SCOPA-PC), while the motor state was evaluated
with the Scales for Outcomes in Parkinson’s Disease-Motor
(SCOPA-Motor). The MDS-UPDRS, specifically part IA, has
been validated using theHamiltonDepression Scale,Hospital
Anxiety and Depression Scale, Lille Apathy Rating Scale, and
Parkinson’s Psychosis Rating Scale, among other scales [6],
as well as the Nonmotor Symptoms Scale [7]. In our study,
high correlation coefficients were found between SEND-PD
scores and similar items of theMDS-UPDRS. Apathy was the
only item showing amoderate correlation. Differences on the
apathy item construct between scales may partially explain
this finding. For instance, item 1.5 from the MDS-UPDRS IA
explicitly assesses the performance of daily activities as well as
the social interactions. On the other hand, the item from the
SEND-PD is focused exclusively on initiating, participating,
or finishing tasks or activities.
Moreover, the correlation between the partial SEND-
PD and neuropsychiatric MDS-UPDRS part IA scores was
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(hallucinations) 0.92 0.24 0.25 0.09 0.13
Total subscale 1
(psychotic symptoms) 0.64 0.30 0.36 0.21 0.19
Item 6
(apathy) 0.23 0.44 0.34 0.67 −0.01
Item 8
(depression) 0.20 0.96 0.47 0.37 0.18
Item 9
(anxiety) 0.25 0.48 0.98 0.31 0.23
Total subscale 2




0.20 0.17 0.21 −0.01 0.83
extremely high (>0.90), demonstrating almost equivalence
between both measures.
Our study has limitations. Since the study was carried out
in a tertiary care setting, a referral bias was present resulting
in an underrepresentation of patients with a more severe
disease.Thus, extrapolation of our findings to this population
should be takenwith caution and comparisonwith the results
of the original study is ballasted by differences in PD severity
between samples. Another limitation is that comparison with
a gold standard evaluation was not performed; thus sensi-
tivity and specificity could not be calculated. Nevertheless,
both the MDS-UPDRS part IA and the SEND-PD have been
previously validated with such instruments and proved to
be adequate for screening purposes. Finally, it should be
mentioned that while the MDS-UPDRS part IA has one item
for cognitive decline assessment, the lack of such domain on
the SEND-PD did not allow any comparison.
5. Conclusion
In conclusion, the present study confirms the data from the
original study and demonstrates that the SEND-PD, as a
whole, is an acceptable, consistent, and valid assessment for
presence and estimation of severity of the neuropsychiatric
disorders associated with PD. In addition, findings indicate
that corresponding items and scores of the SEND-PD and
MDS-UPDRS part IA are strongly associated, reinforcing
the satisfactory convergent validity from previous studies
for both scales. For research purposes, the choice of one
scale over the other will depend greatly on the primary
endpoint, time availability, and personal preferences. The
SEND-PD change over time has yet to be studied. For clinical
use, both scales can be considered equivalent for assessing
hallucinations, psychosis, depression, anxiety, apathy, and
dopaminergic dysregulation syndrome.
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